Upstream Bio

Upstream Bio Inventory

Inventory of Upstream Bio (UPB) as of Oct 19, 2026.

Inventory

-USD

Last updated:

Inventory of Upstream Bio is 2026 - USD. Inventory of Upstream Bio was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Upstream Bio Stock analysis

What does Upstream Bio do? Upstream Bio Inc., based in Waltham, Massachusetts, is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company, which went public on October 11, 2024, is advancing verekitug, a monoclonal antibody targeting TSLP, a key cytokine involved in immune-mediated conditions. It is conducting Phase II trials for severe asthma and chronic rhinosinusitis with nasal polyps, with plans to expand into COPD treatment. Upstream Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Upstream Bio stock

On Eulerpool you can find the complete historical development of Inventory Upstream Bio since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Upstream Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Upstream Bio

All Key Metrics — Upstream Bio